Your browser doesn't support javascript.
loading
The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study.
Brekke, Kristin; Sommerfelt, Maja; Ökvist, Mats; Dyrhol-Riise, Anne Margarita; Kvale, Dag.
Affiliation
  • Brekke K; Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.
  • Sommerfelt M; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway.
  • Ökvist M; Bionor Pharma, Oslo, Norway.
  • Dyrhol-Riise AM; Bionor Pharma, Oslo, Norway.
  • Kvale D; Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.
BMC Infect Dis ; 17(1): 228, 2017 03 24.
Article in En | MEDLINE | ID: mdl-28340570
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: AIDS Vaccines Type of study: Clinical_trials Limits: Humans Language: En Journal: BMC Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2017 Document type: Article Affiliation country: Norway Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: AIDS Vaccines Type of study: Clinical_trials Limits: Humans Language: En Journal: BMC Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2017 Document type: Article Affiliation country: Norway Country of publication: United kingdom